Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

INTRODUCTION Immunocompromised patients have been excluded from initial trials evaluating SARS-CoV-2 mRNA vaccines and there is a critical need to warrant vaccine efficacy in hematopoietic stem cell transplant (HSCT) recipients. In this study, we evaluated antibody responses to 2 doses mRNA SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Maillard, Alexis, Redjoul, Rabah, Klemencie, Marion, Labussière, Hélène, Le Bourgeois, Amandine, d'Aveni, Maud, Berceanu, Anna, Chantepie, Sylvain, Botella, Carmen, Loschi, Michael, Joris, Magalie, Castilla-Llorente, Cristina, Francois, Sylvie, Leclerc, Mathieu, Chevallier, Patrice, Nguyen Quoc, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701412/
http://dx.doi.org/10.1182/blood-2021-149495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701412/
http://dx.doi.org/10.1182/blood-2021-149495

Ejemplares similares